Characterization of a surrogate murine antibody to model anti-human CD3 therapies

Phase I trial of a humanized, Fc receptor nonbinding anti-CD3 antibody, hu12F6mu in patients receiving renal allografts

(2014) Jing Li et al.   mAbs

Long-term amelioration of established collagen-induced arthritis achieved with short-term therapy combining anti-CD3 and anti-tumor necrosis factor treatments

(2012) Fabien Dépis et al.   ARTHRITIS AND RHEUMATISM

A humanised mouse model of cytokine release: Comparison of CD3-specific antibody fragments

(2012) S.L. Malcolm et al.   JOURNAL OF IMMUNOLOGICAL METHODS

Competition for IL-2 between Regulatory and Effector T Cells to Chisel Immune Responses

(2012) Thomas Höfer et al.   Frontiers in Immunology

Induction of Immunological Tolerance by Oral Anti-CD3

(2011) Andre Pires da Cunha et al.   Clinical & Developmental Immunology

Oral tolerance

(2011) Howard L. Weiner et al.   IMMUNOLOGICAL REVIEWS

Otelixizumab in the treatment of Type 1 diabetes mellitus

(2011) Ben Sprangers et al.   Immunotherapy

Anti-CD3 antibodies for type 1 diabetes: beyond expectations

(2011) Jean-François Bach   LANCET

Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial

(2011) Nicole Sherry et al.   LANCET

Human CD3 Transgenic Mice: Preclinical Testing of Antibodies Promoting Immune Tolerance

(2011) C. Kuhn et al.   Science Translational Medicine

Developing combination immunotherapies for type 1 diabetes: recommendations from the ITN-JDRF Type 1 Diabetes Combination Therapy Assessment Group

(2010) J. B. Matthews et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass

(2010) B. Keymeulen et al.   DIABETOLOGIA

Anti-CD3 antibody visilizumab is not effective in patients with intravenous corticosteroid-refractory ulcerative colitis

(2010) W. J. Sandborn et al.   GUT

Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of NI-0401 (a fully human anti-CD3 monoclonal antibody) in patients with moderate to severe active Crohnʼs disease†

(2010) Janneke C. van der Woude et al.   INFLAMMATORY BOWEL DISEASES

Anti-CD3 therapy permits regulatory T cells to surmount T cell receptor–specified peripheral niche constraints

(2010) Junko Nishio et al.   JOURNAL OF EXPERIMENTAL MEDICINE

ANTI-CD3 therapy expands the numbers of CD4+ and CD8+ treg cells and induces sustained amelioration of collagen-induced arthritis

(2009) Clare A. Notley et al.   ARTHRITIS AND RHEUMATISM

Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb teplizumab preserves insulin production for up to 5 years

(2009) Kevan C. Herold et al.   CLINICAL IMMUNOLOGY

Functional Characterization of N297A, A Murine Surrogate for low-Fc Binding Anti-Human CD3 Antibodies

(2009) Debra T. Chao et al.   IMMUNOLOGICAL INVESTIGATIONS

CD3-specific antibody–induced immune tolerance involves transforming growth factor-β from phagocytes digesting apoptotic T cells

(2008) Sylvain Perruche et al.   NATURE MEDICINE